Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups

被引:16
|
作者
Witting, Celeste
Zheng, Jimmy [2 ]
Tisdale, Rebecca L. [1 ,3 ,4 ]
Shannon, Evan [5 ]
Kohsaka, Shun [6 ]
Lewis, Eldrin F. [1 ]
Heidenreich, Paul [1 ,3 ]
Sandhu, Alexander [1 ,3 ,7 ]
机构
[1] Stanford Univ, Dept Med, Stanford, CA USA
[2] Stanford Univ, Sch Med, Stanford, CA USA
[3] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[4] Stanford Univ, Dept Hlth Policy, Stanford, CA USA
[5] David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA
[6] Keio Univ, Dept Cardiol, Sch Med, Tokyo, Japan
[7] Stanford Univ, VA Palo Alto Hlth Care Syst, 870 Quarry Rd Extens, Palo Alto, CA 94304 USA
关键词
disparities; guideline-directed medical therapy (GDMT); heart failure; quality; DISPARITIES; MORTALITY;
D O I
10.1016/j.jchf.2022.08.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND There are sociodemographic disparities in outcomes of heart failure with reduced ejection fraction (HFrEF), but disparities in guideline-directed medical therapy (GDMT) remain poorly characterized.OBJECTIVES This study aimed to analyze GDMT treatment rates in eligible patients with recently diagnosed HFrEF, and to determine how rates vary by sociodemographic characteristics.METHODS This retrospective cohort study included patients diagnosed with HFrEF at Veterans Affairs (VA) hospitals from 2013 to 2019. The authors analyzed GDMT treatment rates and doses, excluding patients with contraindications. Therapies of interest were evidence-based beta-blockers (BBs), renin-angiotensin system inhibitors (RASIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and mineralocorticoid antagonists (MRAs). The authors compared adjusted treatment rates by race and ethnicity, neighborhood social vulnerability, rurality, distance to medical care, and sex.RESULTS The cohort comprised 126,670 VA patients with recently diagnosed HFrEF. The study found that racial and ethnic minorities had similar or higher treatment rates than White patients. Patients residing in socially vulnerable neighborhoods had 3.4% lower ARNI (95% CI: 1.9%-5.0%) treatment rates. Patients residing farther from specialty care had similar rates of GDMT therapy overall, but were less likely to be taking at least 50% of the target doses of either BBs (4.0% less likely; 95% CI: 3.1%-5.0%) or RASIs (5.0% less likely; 95% CI: 4.1%-6.0%) compared with those closer to care.CONCLUSIONS Among VA patients with recently diagnosed HFrEF, the authors did not find that racial and ethnic minority patients were less likely to receive GDMT. However, appropriate dose up-titration may occur less frequently in more remote patients. (J Am Coll Cardiol HF 2023;11:161-172) Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:161 / 172
页数:12
相关论文
共 50 条
  • [41] Heart failure with reduced ejection fraction
    Michelle W. Bloom
    Barry Greenberg
    Tiny Jaarsma
    James L. Januzzi
    Carolyn S. P. Lam
    Aldo P. Maggioni
    Jean-Noël Trochu
    Javed Butler
    Nature Reviews Disease Primers, 3
  • [42] Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction
    Halbach, Marcel
    Hickethier, Tilman
    Madershahian, Navid
    Mueller-Ehmsen, Jochen
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (12) : 1465 - 1469
  • [43] Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
    Gonzalez, Oscar Eduardo Ospina
    Mejia, Diana Catalina Llanos
    Kaplinsky, Edgardo
    Barbagelata, Alejandro
    Perrone, Sergio
    DRUGS IN CONTEXT, 2023, 12
  • [44] Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction
    Al-Mohammad, Abdallah
    ESC HEART FAILURE, 2019, 6 (04): : 878 - 883
  • [45] Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Inciardi, Riccardo M.
    Fonarow, Gregg C.
    McMurray, John J. V.
    Solomon, Scott D.
    CIRCULATION, 2022, 145 (23) : 1741 - 1743
  • [46] The effect of kidney function on the optimization of medical therapy and on mortality in heart failure with reduced ejection fraction
    Fanni, Banfi-Bacsardi
    Mate, Vamos
    Zsuzsanna, Majoros
    Marton, Toeroek Gabor
    David, Pilecky
    Zoltan, Duray Gabor
    Gabor, Kiss Robert
    Noemi, Nyolczas
    Balazs, Muk
    ORVOSI HETILAP, 2023, 164 (35) : 1387 - 1396
  • [47] Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction?
    Greene, Stephen J.
    Khan, Muhammad Shahzeb
    Butler, Javed
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 338 - 341
  • [48] EFFECTS OF SEX AND RACE ON GUIDELINE DIRECTED MEDICAL THERAPY FOR HEART FAILURE WITH REDUCED EJECTION FRACTION
    Kancharla, S.
    Oshunbade, A. A.
    Long, R. C.
    Hernandez, G.
    Lennep, B.
    Papadimitriou, L.
    Moore, C.
    Butler, J.
    Hall, M. E.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 495 - 495
  • [49] Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Dixit, Neal M.
    Truong, Katie P.
    Vaduganathan, Muthiah
    Ziaeian, Boback
    Fonarow, Gregg C.
    JACC-HEART FAILURE, 2024, 12 (07) : 1226 - 1237
  • [50] Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy
    Nijst, Petra
    Verbrugge, Frederik H.
    Martens, Pieter
    Bertrand, Philippe B.
    Dupont, Matthias
    Francis, Gary S.
    Tang, W. H. Wilson
    Mullens, Wilfried
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2017, 18 (03)